BRTX - Company ID 0001505497
The table below shows BioRestorative Therapies, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $23.17K | $11.80K | $303.30K | $25.00K | $233.60K | $89.10K |
| Cost of revenue | $7.38K | $10.57K | $8.73K | $2.91K | $18.24K | $6.49K |
| Gross profit | $15.79K | $1.23K | $294.57K | $22.09K | $215.36K | $82.61K |
| R&D | $1.93M | $2.59M | $2.23M | $2.65M | $1.45M | $1.45M |
BioRestorative Therapies, Inc. reported annual revenue of $359.70K for fiscal year 2025. That is down 10.3% from $401.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $36.35K (FY 2016) to $359.70K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $1.48M | $1.12M | $1.37M | $2.18M | $1.05M | $1.10M |
| Operating income | -$3.39M | -$3.71M | -$3.31M | -$4.81M | -$2.29M | -$2.47M |
| Income tax | - | - | - | - | - | - |
| Net income | -$2.15M | -$3.04M | -$2.66M | -$5.34M | -$1.09M | -$4.03M |
| EPS (diluted) | -$0.12 | -$0.33 | -$0.30 | -$0.64 | -$0.13 | -$0.50 |